NCT00590642

Augmentation in Tx-resistant OCD: an Open Label Trial

Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Creighton University · Academic / Other
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study examines the use of Acamprosate (Campral(R)) in the treatment of Obsessive Compulsive Disorder (OCD). The treatment of this condition is difficulty and a large percentage of patients fail to respond to medications and have residual symptoms. Such patients are referred to as having treatment resistant OCD.

Detailed description

A patient will receive study drug for about 12 weeks. Throughout the study, the study doctor, on best medical judgment, may gradually increase or decrease the dose of the study medication. The adjustments will dependent on the subject's response and whether the subject has side effects. Once the subject has completed treatment under this study, the subject may resume standard treatment for his/her obsessive compulsive disorder by their regular doctor.

Conditions

• Obsessive Compulsive Disorder

Timeline

• Start date: 2006-04-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2008-01-10
• Last updated: 2009-12-01

Locations

1 site across 1 country: United States